Cardiac Effects of Adjuvant Therapy for Early Breast Cancer

Seminars in Oncology

Volumn 30, Issue 6, 2003, Pages 730-739

  Theodoulou, Maria ^a   Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIESTROGEN; ANTIMETABOLITE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE; IDARUBICIN; MITOXANTRONE; PACLITAXEL; RAZOXANE; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; EARLY DIAGNOSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MASTECTOMY; MORBIDITY; MORTALITY; MYOCARDITIS; PATIENT CARE; PERICARDITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TACHYCARDIA; THROMBOSIS; TREATMENT PLANNING;

EID: 0346993613     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.024     Document Type: Article

References (68)

1. American Cancer Society (ed): Breast Cancer Facts and Figures, 2001-2002. Atlanta, GA, American Cancer Society, 2002
2. Yancik R, Ries LA: Aging and cancer in America. Hematol Oncol Clin North Am 14:17-3, 2000
3. Fisher B, Anderson S, Redmond C, et al: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456-1461, 1995
4. Delouche G, Bachelot F, Premont M, et al: Conservation treatment of early breast cancer: Long term results and complications. Int J Radiat Oncol Biol Phys 13:29-34, 1987
5. Schultz-Hector S: Radiation-induced heart disease: Review of experimental data on dose response and pathogenesis. Int J Radiat Biol 61:149-160, 1992
6. Rutqvist LE, Liedberg A, Hammar N, et al: Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 40:359-363, 1998
7. Cuzick J, Stewart H, Rutqvist L, et al: Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994
8. Kaplan H: Radiotherapy, in Kaplan H (ed): Hodgkin's Disease. Cambridge, MA, Harvard University Press, 1972, pp 336-391
9. Stewart J, Cohen K, Fajardo L, et al: Radiation-induced heart disease: A study of twenty-five patients. Radiology 89: 302-310, 1967
10. Lobo R: Hormones, hormone replacement therapy and heart disease, in Douglas P (ed): Cardiovascular Health and Disease in Women. Philadelphia, PA, Saunders, 1993, pp 153-174
11. Ali M, Ewer M: Cardiovascular problems in the patient with cancer: Radiation-related heart disease. Prim Care Center 9:11-15, 1989
12. Ewer MS, Benjamin RS: Cardiac complications, in Holland JF, Frei E, Bast RC, et al (eds): Cancer Medicine (ed 5). Hamilton, Canada, Decker, 2000, pp 2324-2339
13. Ferri G, Dusi U: Radiazoni ionizzant e cuore: Part I. Quad Radiol 30:1007-1032, 1965
14. Amromin G, Gildenhorn H, Solomon R, et al: The synergism of x-irradiation and cholesterol-fat feeding on the development of coronary artery lesions. J Atherosclerosis Res 4:325-34, 1964
15. Stewart R, Fajardo L, Gillette S, et al: Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31:1205-1211, 1995
16. Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355:1757-1770, 2000
17. Paszat L, Mackillop W, Groome P, et al: Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance, Epidemiology, and End-Results cancer registries. J Clin Oncol 16:2625-2631, 1998
18. Nixon AJ, Manola J, Gelman R, et al: No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol 16:1374-1379, 1998
19. Vallis KA, Pintilie M, Chong N, et al: Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 20:1036-1042, 2002
20. Shapiro CL, Hardenbergh PH, Gelman R, et al: Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16:3493-3501, 1998
21. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746-2753, 2001
22. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive lymph nodes. Ten-year results. JAMA 273:542-547, 1995
23. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
24. Doroshow JH, Locker GY, Myers CE: Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 65:128-135, 1980
25. Keefe D: Anthracycline-induced cardiomyopathy. Semin Oncol 28:2-7, 2001 (suppl 12)
26. Fumoleau P, Kerbrat P, Romestaing P, et al: Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French adjuvant study 01 trial. J Clin Oncol 21:298-305, 2003
27. Benjamin R, Chawla S, Ewer M, et al: Adriamycin cardiac toxicity-An assessment of approaches to cardiac monitoring and cardioprotection, in Hacker M, Lazo J, Tritton T (eds): Organ Directed Toxicities of Anticancer Drugs. Boston, MA, Martinus Nijhoff, 1988, pp 44-55
28. Budman DR, Berry DA, Cirrincione CT, et al: Dose and dose intensity as determinants of the outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205, 1998
29. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390A)
30. Von Hoff DD, Layard MW, Basa P, et al: Risk Factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
31. Aviles A, Arevila N, Diaz Maqueo JC, et al: Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 11:275-279, 1993
32. Lefrak EA, Pitha J, Rosenheim S, et al: A clinicopatologic analysis of Adriamycin cardiotoxicity. Cancer 32:302-314, 1973
33. Zambetti M, Moliterni A, Materazzo C, et al: Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19:37-43, 2001
34. Bristow M, Thompson P, Martin R, et al: Early anthracycline cardiotoxicity. Am J Med 65:823-832, 1978
35. Gharib MI, Burnett AK: Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Failure 4:235-242, 2002
36. Frishman WH, Sung HM, Yee HC, et al: Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer 21:301-360, 1997
37. Goethals I, DeWinter O, DeBondt P, et al: The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. Ann Oncol 13:1331-1339, 2002
38. Steinherz LJ, Steinherz PG, Tan C, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
39. Singhal P, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998
40. Jensen BV, Skovsggard T, Nielsen SL: Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13:699-709, 2002
41. Lee BH, Goodenday LS, Muswick GJ, et al: Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 9:184-188, 1987
42. Mortensen SA, Olsen HS, Baandrup U: Chronic anthracycline cardiotoxicity: Haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. Br Heart J 55:274-282, 1986
43. Manson JW, Bristow MR, Billingham ME, et al: Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: Superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 68:857-864, 1978
44. Ewer M, Carrasco C, Mackay B, et al: Cardiac biopsy procedures at a cancer center. Proc Am Soc Clin Oncol 10:336, 1991 (abstr)
45. Cardinale D, Sandri MT, Martinoni A, et al: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710-715, 2002
46. Bernardini N, Agen C, Favilla S, et al: Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor. J Endocrinol Invest 15:79-84, 1992
47. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
48. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in the first-line treatment of HER2 overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
49. Slamon DJ, Leyland-Jones B, Shak S, et al: Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer: A phase III, multinational, randomized controlled trial. N Engl J Med 344:783-792, 2001
50. Norton L, Slamon D, Leyland-Jones B, et al: Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 18:127a, 1999 (abstr 483)
51. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
52. Gelmon K, Mackey J, Verma S, et al: Efficacy and safety of Herceptin in women with HER2-positive metastatic breast cancer who have progressed on a prior Herceptin-containing regimen. Breast Cancer Res Treat 76:S113, 2002 (suppl, abstr 440)
53. Keefe D: Trastuzumab-associated cardiotoxicity. Cancer 95:1592-1600, 2002
54. Dieras V, Fumoleau P, Lotz JP, et al: Previous cumulative anthracycline dose is the main determinant of LVEF decrease in breast cancer patients treated with trastuzumab (Herceptin): Results of a French compassionate use program. Breast Cancer Res Treat 76:S110, 2002 (suppl, abstr 425)
55. Feldman AM, Lorell BH, Reis SE: Trastuzumab in the treatment of metastatic breast cancer. Anticancer therapy versus cardiotoxicity. Circulation 102:272-274, 2000
56. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intem Med 96:133-139, 1982
57. Torti FM, Bristow MR, Howes AE, et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99: 745-749, 1983
58. Weiss AJ, Metter GE, Fletcher WS, et al: Studies on Adriamycin using weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813-822, 1976
59. Weiss AJ, Manthel RW: Experience with the use of Adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 40:2046-2052, 1997
60. Chlebowski RT, Paroly WS, Pugh RP, et al: Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47-51, 1980
61. Niemann B, Mross K, Drevs J, et al: The pharmacokinetic profile of liposome-encapsulated doxorubicin (TLC D-99; Myocet). Proc Am Soc Clin Oncol 20:117a, 2001 (abstr 463)
62. Harris L, Batist G, Belt R, et al: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast cancer. Cancer 94:25-36, 2002
63. Batist G, Ramakrishnan G, Rao CS, et al: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444-1454, 19:2001
64. Wigler N, Inbar M, O'Brien M, et al: Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 21:45a, 2002 (abstr 177)
65. Theodoulou M, Campos S, Batist, G, et al: TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): Final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 21:55a, 2002 (abstr 216)
66. Speyer JL, Green MD, Kramer E, et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745-752, 1988
67. Speyer JL, Green MD, Seleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992
68. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997